Why This Matters
For most Americans, the Canadian wildfire smoke that blanketed the Midwest and Northeast from July 14 through July 20, 2026, was an inconvenience. Schools kept children indoors. The Chicago lakefront was deserted. Detroit and Minneapolis recorded their highest air quality index readings in 27 years. The Washington, D.C. area recorded PM2.5 concentrations near 200 micrograms per cubic meter, triggering Code Purple alerts. More than 120 million Americans were advised to limit outdoor activity.
For people receiving medication-assisted treatment (MAT) for opioid use disorder, the same smoke event carried a different kind of danger, one that is rarely discussed in air quality emergency coverage.
Buprenorphine and methadone are not optional supplements. They are FDA-approved medications that prevent opioid withdrawal, suppress cravings, and keep people alive. Buprenorphine requires regular clinic or pharmacy visits to maintain an active prescription. Methadone for opioid use disorder can only be dispensed through federally regulated opioid treatment programs, and requires in-person visits under most existing regulatory frameworks. When air quality emergencies make travel dangerous or impossible, these access requirements become life-threatening barriers.
What We Know So Far
The research foundation for this concern is not theoretical. A 2022 analysis published in peer-reviewed literature examined what happened to patients receiving long-term opioid prescriptions, including buprenorphine for opioid use disorder, in the aftermath of the 2018 Camp Fire in Northern California, the deadliest wildfire in state history. Using California's prescription drug monitoring program data, researchers at the University of California, Davis found that in the ZIP codes most severely impacted by the fire, the proportion of patients who experienced a late fill, representing a gap in their medication access of more than two weeks, quadrupled in the weeks following the disaster, according to reporting in Think Global Health and NPR.
Iraklis Tseregounis, a drug use researcher at UC Davis and lead author of the 2022 analysis, described the stakes directly: "They need to have continued access to them; otherwise they could have fatal consequences."
The pattern is not unique to California wildfires. After Superstorm Sandy in 2012, one study estimated that 70% of New York-area patients who relied on opioid recovery medications could not access an adequate supply. In Puerto Rico, overdose reports increased in the two years following Hurricane Maria in 2017, according to NPR's reporting.
Where the Risk Is Highest Right Now
The Canadian wildfire smoke event of July 14-20, 2026, was not just a hazy sky. According to The Weather Company, the event produced the highest levels of smoke particulate pollution in nearly three decades for several cities from Minnesota to Washington, D.C. On July 16, Detroit, Minneapolis, and Chicago were the three most polluted major cities in the world by IQAir's calculations. The PM2.5 concentration in Baltimore and Washington approached 200 micrograms per cubic meter — well above the 55 micrograms per cubic meter threshold that the EPA defines as "very unhealthy for all groups."
Detroit, Chicago, and Cleveland are also cities with substantial populations receiving medication-assisted treatment. The Midwest is among the regions hardest hit by the opioid epidemic, with Ohio, Michigan, Illinois, Indiana, and West Virginia consistently ranking among the states with the highest opioid overdose death rates. The intersection of the smoke's geographic reach and the concentration of opioid treatment patients is direct.
What Doctors and Experts Say
An April 2026 editorial in the American Journal of Public Health argued that existing regulations make medication-assisted treatment difficult enough to access under normal conditions and nearly impossible during a disaster. The editorial authors proposed factoring MAT access into disaster response plans, including stocking rescue vehicles with buprenorphine, adding backup generators to opioid treatment clinics, and training volunteer disaster responders to administer recovery medications.
Elizabeth Cerceo, climate health director at Rowan University's Cooper Medical School and co-author of the AJPH editorial, told NPR that as climate events become longer and more severe, existing harm-reduction interventions may become less effective at managing surges in overdose risk.
Methadone's legal structure is central to this vulnerability. Unlike buprenorphine, which can be prescribed by any licensed clinician and filled at a retail pharmacy, methadone for opioid use disorder can only be dispensed at federally regulated opioid treatment programs through daily in-person visits, except for take-home doses granted at specific levels of treatment compliance. When those programs close, or when patients cannot safely travel to them, the medication stops.
Toni Brewer, an Asheville resident who had been 18 months into recovery from opioid addiction when Hurricane Helene struck in 2024, described her experience running low on Suboxone in NPR reporting: "It's terrifying just to have that feeling again of, 'I need this, and I'll do whatever it takes to get this.'"
What the Evidence Shows and What It Does Not
The 2022 California wildfire analysis examined prescription opioid access broadly, including both pain medications and opioid use disorder treatments. It found significant disruption in the highest-impact areas around the Camp Fire. It did not isolate buprenorphine or methadone separately from all prescription opioids, and it cannot directly predict what will happen during smoke events that do not destroy the surrounding infrastructure the way a wildfire does.
An air quality emergency is different from a direct disaster: clinics remain standing, but patients cannot safely travel to them. The magnitude of MAT disruption from a smoke-only event, without property destruction or evacuation, has not been formally studied. The biological risk of stopping MAT abruptly, however, is well established and does not depend on the reason for the gap.
MedicalDaily Evidence Check
- Data source: 2022 California prescription drug monitoring program analysis (Tseregounis et al.); NPR reporting April 28, 2026; AJPH editorial April 2026; Think Global Health; NASA/EPA wildfire smoke data July 14-20, 2026
- What it shows: Late prescription fills for opioid medications quadrupled in Camp Fire impact zones; similar disruptions documented after Hurricane Sandy, Hurricane Helene, and Hurricane Maria; Canadian wildfire smoke affected 120M+ Americans in the same geographic regions as high opioid overdose burden states
- What it does not prove: That the July 2026 smoke event has already caused MAT disruptions; that disruption from smoke-only events causes the same magnitude of access failure as physical disaster events
-
What readers should know: The regulatory structure of methadone dispensing and the travel requirements for buprenorphine refills create genuine risk during any event that limits safe outdoor movement
Who Faces the Greatest Risk?
The populations most vulnerable to MAT disruption during air quality emergencies include:
- People receiving methadone maintenance therapy, who require daily in-person visits to federally regulated opioid treatment programs under standard conditions
- People taking buprenorphine on a shorter refill schedule (weekly or biweekly) who have not yet qualified for extended take-home supplies
- People without personal vehicles in urban areas where public transit may be disrupted or where outdoor movement is unsafe
- People with respiratory conditions such as asthma or COPD, for whom smoke exposure is independently dangerous, compounding the barrier to safe travel
-
People experiencing housing instability or homelessness, who have less ability to shelter in place and fewer options for alternative medication access
Symptoms and Warning Signs to Watch For
For people in opioid use disorder treatment who miss medication doses, withdrawal symptoms typically begin within 12 to 24 hours (for short-acting medications) and may include:
- Muscle aches, cramps, or severe joint pain
- Sweating, chills, or goosebumps
- Nausea, vomiting, or diarrhea
- Anxiety, restlessness, or insomnia
- Intense drug cravings
Opioid withdrawal is rarely directly fatal in otherwise healthy adults, but it significantly increases the risk of relapse and subsequent fatal overdose, particularly because tolerance drops rapidly during a period without opioids, meaning a previously tolerated dose can become lethal.
What You Can Do Now
For people currently receiving MAT:
- If you or someone you support is receiving methadone or buprenorphine treatment in an area under an air quality advisory, contact your treatment program or prescriber now to ask about emergency take-home dose provisions or telehealth prescription refills.
- Ask whether your program has a disaster protocol. Programs that received emergency waivers during COVID-19 allowing extended take-home methadone doses may have retained or reinstated similar policies.
- Call SAMHSA's National Helpline at 1-800-662-4357 (free, confidential, 24/7) if you are unable to reach your treatment provider during an emergency.
- Naloxone (Narcan) access is critical. If you are at risk of relapse during a treatment gap, ensure that someone in your household has naloxone and knows how to use it.
- Harm reduction organizations and local health departments in major cities often have emergency protocols during disaster periods; call 311 in many cities to reach local health resources.
For clinicians and public health officials:
- Proactively contact high-risk patients before extended air quality emergencies to arrange take-home supplies or telehealth refill visits.
-
Advocate for emergency MAT protocols that do not require in-person visits during declared air quality emergencies, consistent with the COVID-19 waiver framework that demonstrated safety at scale.
Cost and Access: What Patients Should Know
Telehealth buprenorphine prescribing is now available from multiple licensed providers. During air quality emergencies, telehealth is not only more convenient — for people with respiratory conditions or without reliable transportation, it may be the only safe access pathway.
Methadone take-home doses require demonstrated treatment stability and compliance. Patients who have not yet qualified for extended take-home schedules should speak with their treatment program about whether emergency circumstances can accelerate that review. During COVID-19, the DEA and SAMHSA granted blanket waivers permitting up to 28 days of take-home methadone for stable patients and 14 days for less stable patients. Those waivers have since expired, but some states have maintained more flexible policies.
What Happens Next
The AJPH editorial's recommendations for building MAT access into disaster preparedness planning have not yet been adopted as national policy. SAMHSA has the regulatory authority to issue emergency guidance permitting extended take-home medications and telehealth dispensing during formally declared emergencies. Whether the July 2026 Canadian wildfire smoke event triggers any such guidance remains to be determined.
MedicalDaily will continue monitoring both the air quality situation and any emergency MAT policy responses issued by SAMHSA or state health departments.
The Bottom Line
More than 120 million Americans spent the week of July 14 under hazardous air quality warnings from Canadian wildfire smoke. For most, the guidance was to stay indoors and limit outdoor activity. For people receiving medication-assisted treatment for opioid use disorder, that same guidance can mean a forced break in the medications that keep them alive. Research from the 2018 Camp Fire documented a fourfold increase in treatment lapses in the hardest-hit areas. The regulatory structure of opioid treatment, particularly for methadone, creates vulnerability that air quality emergencies expose. No national guidance has been issued addressing this intersection. It should be.
